Healio (7/27, Gramigna) reports, “Vortioxetine appeared to reduce cognitive impairment among patients with major depressive disorder [MDD],” investigators concluded in a systematic review that “included 26 clinical trials of antidepressants and other therapeutic agents among populations with MDD.” The findings were published online July 21 in the Journal of Clinical Psychiatry. (SOURCE: APA Headlines)